10-Q: Syndax Pharmaceuticals Reports Q1 2024 Results, Advances Key Drug Candidates

Syndax Pharmaceuticals reported a net loss of $72.4 million for the first quarter of 2024, while also highlighting progress in the development of its key drug candidates, revumenib and axatilimab.

Summary

• Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company, announced its financial results for the first quarter of 2024, reporting a net loss of $72.4 million, compared to a net loss of $41.1 million for the same period in 2023.
• The company's research and development expenses increased to $56.5 million, up from $34.1 million in the prior year, primarily driven by increased spending on revumenib and personnel costs.
• Selling, general, and administrative expenses also rose to $23.0 million, compared to $12.0 million in the first quarter of 2023, due to increased commercialization-related activities and personnel costs.
• As of March 31, 2024, Syndax had cash, cash equivalents, and short and long-term investments totaling $522.0 million.
• The company is advancing its two lead product candidates, revumenib and axatilimab, with regulatory submissions under review by the FDA.
• The Prescription Drug User Fee Act (PDUFA) target action date for revumenib is September 26, 2024, and for axatilimab is August 28, 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive progress in clinical development and regulatory submissions, the increased net loss and reliance on external funding are concerning. The sentiment is neutral to slightly negative.

Positives

• The FDA granted Priority Review for both revumenib and axatilimab, indicating a potentially faster path to approval.
• Enrollment is complete in the AUGMENT-101 trial for mNPM1 AML, with topline data expected in Q4 2024.
• The company has a strong cash position of $522.0 million, which should support operations for at least the next 12 months.
• Positive results from a subset of the pivotal AUGMENT-101 trial in pediatric patients with R/R KMT2Ar AML and acute lymphoid leukemia (ALL) treated with revumenib were featured in a plenary session at the American Society of Pediatric Hematology/Oncology (ASPHO) Annual Meeting in April 2024.

Negatives

• The company's net loss increased significantly to $72.4 million in Q1 2024, compared to $41.1 million in Q1 2023.
• Research and development expenses increased substantially, driven by revumenib development and personnel costs.
• Selling, general, and administrative expenses also increased significantly due to commercialization preparations.
• The company has no product revenue and is reliant on external funding.

Risks

• The company is subject to risks associated with obtaining regulatory approval for its product candidates.
• There are risks associated with the commercialization of its product candidates, including market acceptance and competition.
• The company relies on third-party suppliers and Incyte for manufacturing and distribution of its clinical drug supplies.
• The company is subject to risks associated with the current inflationary environment and rising interest rates.
• The company is subject to risks associated with the ongoing war between Russia and Ukraine and the war in Israel.
• The company is subject to risks associated with the inherent uncertainty of clinical success.

Future Outlook

The company expects to continue to advance the development of its drug candidates, with regulatory decisions expected for both revumenib and axatilimab in the coming months. Syndax also plans to initiate a pivotal trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed mNPM1 or KMT2Ar acute leukemia patients unfit to receive intensive chemotherapy by year-end 2024.

Management Comments

• The company is focused on advancing its two lead product candidates, revumenib and axatilimab.
• The company is preparing for potential commercial launches of both revumenib and axatilimab.
• The company is leveraging the technical and business expertise of its management team and scientific collaborators to license, acquire and develop additional therapeutics to expand its pipeline.

Industry Context

Syndax's progress with revumenib and axatilimab is occurring within a competitive landscape of cancer therapies. The company is focused on specific patient populations with unmet needs, such as those with KMT2A-rearranged leukemia and chronic graft-versus-host disease. The company is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer.

Comparison to Industry Standards

• Syndax's increased R&D spending is typical for a clinical-stage biotech company advancing multiple drug candidates.
• The company's cash position is relatively strong compared to other companies of similar size, providing a runway for continued development.
• The PDUFA dates for revumenib and axatilimab are within the typical timeframe for FDA reviews, but the actual approval timelines can vary.
• The company's collaboration with Incyte is a common strategy in the biotech industry to share development costs and commercialization risks, similar to partnerships between companies like Gilead and Galapagos, or AbbVie and Genmab.
• The company's focus on specific patient populations with unmet needs is a common strategy in the biotech industry, similar to companies like Agios and Blueprint Medicines.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased net loss, but encouraged by the progress in clinical development.
• Employees may be impacted by the company's financial performance and future growth plans.
• Patients may benefit from the potential approval of new therapies for cancer and fibrotic diseases.
• Suppliers and creditors may be impacted by the company's financial performance and ability to pay its obligations.

Next Steps

• The company will continue to advance the development of revumenib and axatilimab.
• The company will prepare for potential commercial launches of both revumenib and axatilimab.
• The company will continue to enroll patients in ongoing clinical trials.
• The company will initiate a pivotal trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed mNPM1 or KMT2Ar acute leukemia patients unfit to receive intensive chemotherapy by year-end 2024.
• The company expects topline data from the AUGMENT-101 trial in Q4 2024.

Key Dates

Keywords

Syndax Pharmaceuticals, revumenib, axatilimab, KMT2A, AML, ALL, cGVHD, FDA, PDUFA, BLA, NDA, clinical trials, biopharmaceutical, oncology, hematology